SGLT2 inhibitors lower glucose by making the kidney excrete it. They also raise glucagon and increase the reabsorption of ketones by the renal tubule, which favours ketone production [3]. When insulin is relatively deficient, as in acute illness, fasting or after a reduction in insulin dose, ketoacidosis can develop while glucose stays near normal because it continues to be lost in the urine. The risk is small but real [4], and euglycaemic ketoacidosis has become more frequent as these drugs are used more widely for diabetes, heart failure and kidney disease [2].
Traditional definitions of DKA required a glucose above 250 mg/dL (13.9 mmol/L) [12]. The 2024 consensus from the ADA, EASD, JBDS, AACE and the Diabetes Technology Society instead requires a glucose of 11.1 mmol/L (200 mg/dL) or more or known diabetes, a blood beta-hydroxybutyrate of 3.0 mmol/L or more, and a pH below 7.3 or bicarbonate below 18 mmol/L [1]. A patient with known diabetes and ketoacidosis meets the definition whatever the glucose.